Tricia, Amanda, and Josh discuss SECURED Results
SecurAcath® is Superior to Standard of Care in Newly Published Randomized Controlled Clinical Study
Securement to prevent non-cuffed central venous catheter dislodgement in pediatrics The SECURED superiority randomized clinical trial
“Catheter dislodgement is a major clinical problem for our pediatric patients, with potentially life-threatening consequences. The results of this study clearly show SecurAcath reduces dislodgement and saves money, therefore, SecurAcath should be used preferentially over adhesive device securement,” said Tricia Kleidon, RN, MNursePrac, lead author of the study publication.
Nova Scotia Health – Quality Award Winner
EXCELLENCE IN PATIENT SAFETY AWARD
Noting that many patients with Peripherally Inserted Central Catheters (PICC) lines were returning to hospital due to their line becoming dislodged, migrated, eroded at the insertion site or infected, the team working in the Ambulatory Treatment Center (ATC) at the Aberdeen Regional Hospital initiated a trial using a new product, SecurAcath, a subcutaneous anchor system for PICC lines. Following the implementation of this patient safety focused trial, the team has measured a marked improvement in patient care, reduction of patient return rates, improvement of the effectiveness and efficiency of the resources and nursing care time both in hospital and the community.
Shawn and Melissa discuss Quality Award
Vascular Access Device Securement – State of the Art
WoCoVA Meet the Experts webinar recording. Watch three excellent presentations on the latest in VAD securement followed by Q&A.
Subcutaneous anchorage of PICCs – Fabrizio Brescia
Vascular Access Device (VAD) Securement in Neonates and Children – Amanda Ullman
Current Options for VAD Securement – Evan Alexandrou
SecurAcath® Awarded Innovative Technology Contract from Vizient
Vizient is the largest member-driven health care performance improvement company in the U.S. The contract was based on the recommendation of SecurAcath by hospital experts who serve on one of Vizient’s member-led councils that identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety or improve business operations of health care organizations. Vizient currently serves more than 50% of the nation’s acute care providers and 95% of the nation’s academic medical centers.
Catheter Securement Choice Does Affect Central Line-Associated Bloodstream Infection Risk
SecurAcath Significantly Reduces CLABSI Risk
Recent study in AJIC* showed an adhesive catheter securement device had a 288% increase in risk of CLABSI compared to the SecurAcath.
CLABSIs yield tremendous negative consequences affecting patients and health care facilities globally. The CDC estimates the annual cost of CLABSI is more than $1 billion, the cost per patient is more than $16,000.
